99Tcm-甲氧基异丁基异腈显像在分化型甲状腺癌随访中的应用

邱李恒 ,  林岩松 ,  李方 ,  蒙增寿

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2009,  33 > 5: (275-278)  
引用本文:
shu
Citation:
shu

99Tcm-甲氧基异丁基异腈显像在分化型甲状腺癌随访中的应用

  • 中国医学科学院北京协和医院核医学科, 北京 100730

The value of 99Tcm-methoxyisobutylisonitrile in follow-up of patients with differentiated thyroid carcinoma

  • Department of Nuclear Medicine, Peking Union Medical University Hospital, Beijing 100730, China

  • 摘要: 分化型甲状腺癌(DTC)在经过手术、放射性碘治疗、甲状腺激素抑制治疗后,仍需终身随诊。目前DTC的日常随诊方法如常规影像学方法、甲状腺球蛋白测定和131I全身显像仍有其不足之处,临床上常常发现一些患者存在不摄碘的失分化病灶,定位这些失分化的病灶,对确定患者的进一步治疗至关重要。肿瘤阳性显像剂99Tcm-甲氧基异丁基异腈(99Tcm-MIBI),由于其良好的物理和剂量测量方面的特性,价格便宜,国内外对其在DTC随访中的作用做了大量基础及临床研究。本综述主要从原理、显像方法、显像结果分析、优势介绍99Tcm-MIBI显像在DTC随访的应用。
    Abstract: Patient suffered from differentiated thyroid carcinoma(DTC)needs lifetime follow-up even after going through the thyroidectomy,postoperative 131I treatment,thyroid stimulating hormone suppressing therapy.There are disadvantages in DTC routine follow-up,such as conventional radiologieal studies,measurement of serum thyrogiobulin and 131I scintigraphy.It is not rare for us to see patients with dedifferentiated metastases which with no radioiodine uptake,and how to locate these dedifferentiated metastases is of great importance for making further treatment plan.Tumor imaging agent 99Tcm-methoxyisobutylisonitrile(99Tcm-MIBI)is widely used in the clinical and laboratories research of DTC in domestic and overseas,for its excellent physical and dosimetric characteristics and reasonable price.This review relates the application of 99Tcm-MIBI imaging in DTC follow-up,and focuses on its imaging mechanism,clinical methods,imaging interpretation,and the advantages.
  • [1] Cooper DS,Doherty GM,Haugen BR,et al.Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid,2006,16(2):109-142.
    [2] Salvatore B,Paone G,Klain M,et al.Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.Q J Nucl Med Mol Imaging,2008,52(1):2-8.
    [3] Mausberg R,Crawford B,Uren RF,et al.Minimally invasive radioguided surgery for recurrent thyroid cancer using iodine-123.Clin Nucl Med,2005,30(1):43-44.
    [4] Fujie S,Okumura Y,Sato S,et al.Diagnostic capabilities of I-131,Tl-201,and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy.Acta Med Okayama,2005,59(3):99-107.
    [5] Noh JY.Predictive value of serum thyroglobulin and diagnostic imaging in post-surgical follow-up of differentiated thyroid cancer.Nippon Riusho,2007,65(11):2069-2072.
    [6] Moretti JL,Hauet N,Caglar M,et al.To use MIBI or not to use MIBI? That is the question when assessing tumour cells.Eur J Nucl Med Mol Imaging,2005,32(7):836-842.
    [7] Miyamoto S,Kanji K,Misaki T,et al.Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma.J Nucl Med,1997,38(3):352-356.
    [8] Ronga G,Ventroni G,Montesano T,et al.Sensitivity of[99mTc]methoxyisobutylisonitrile scan in patients with metastatic differentiated thyroid cancer.Q J Nucl Med Mol Imaging,2007,51(4):364-371.
    [9] Wong KT,Choi PT,Lee YY,et al.Current role of radionuclide imaging in differentiated thyroid cancer.Cancer Imaging,2008,10(8):159-162.
    [10] Zuijdwijk MD,Vogel WV,Corsteus FH,et al.Utility of fluoredeoxyglucose-PET in patients with differentiated thyroid carcinoma.Nucl Med Commun,2008,29(7):636-641.
    [11] Fujie S,Okumura Y,Sato S,et al.Diagnostic capabilities of I-131 T1-201 and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy.Acta Med Okayama,2005,59(3):99-107.
    [12] Hsu CH,Liu FY,Yen RF,et al.Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels hut negative I-131 whole body scan.Endocr Res,2003,29(1):9-15.
    [13] Wu HS,Huang WS,Liu YC,et al.Comparison of FDG-PET and technetium-99m MIBI SPECT metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan.Anticancer Res,2003,23(5b):4235-4238.
    [14] Kücük ON,Gültekin SS,Aras G,et al.Radioiodine whole-body scans,thyroglabulin levels,99Tcm-MIBI scans and computed tomography:results in patients with lung metastases from differentiated thyroid cancer.Nucl Med Commun,2006,27(3):261-266.
    [15] Miller DD,Heyl BL,Walsh RA.Lung uptake of technetium-99m hexamibi isonitrile during acute reversible ischemie left vantricular dysfunction in conscious dogs.Circulation,1988,78(suppl):Ⅱ-387.
    [16] Rubello D,Piotto A,Pagetta C,et al.(99m)Tc-MIBI radio-guided surgery for recurrent thyroid carcinoma:technical feasibility and procedure,and preliminary clinical results.Eur J Nucl Med Imaging,2002,29(9):1201-1205.
    [17] Casara D,Rubello D,Saladini G,et al.Different features of pulmonary metastases in differetiated thyroid cancer:natural history and multivariate statistical analysis of prognostic variables.J Nucl Med,1993,34(10):1626-1631.
    [18] 高克加,王建华,叶智卫,等.99mTc-MIBI显像对甲状腺癌疗效的评估价值.上海医学,2002,25(2):89-91.
    [19] 王玉君,赵彦辉,崔亚利.99mTc-MIBI全身显像在治疗分化型甲状腺癌转移灶中的应用价值.实用肿瘤学杂志,2008(4):337-338.
    [20] 高识,马庆杰,孙辉,等.99Tcm-甲氧基异丁基异腈(MIBI)显像与甲状腺癌远处转移的关系研究.中国老年学杂志,2006,26(9):1196-1197.
    [21] 王强,余永利,高秀丽,等.甲状腺癌术后患者颈淋巴结转移影像学比较研究.上海交通大学学报:医学版,2009,29(9):1085-1087.
    [22] Rubello D,Salvatori M,Pelizzo MR,et al.Radio-guided surgery of differentiated thyroid cancer using(131)I or 99mTc-sestamibi.Nucl Med Commum 2006,27(1):1-4.
    [23] Rubello D,Pelizzo MR,Casara D,et al.Radio-guided surgery for non-131I-avid thyroid cancer.Thyroid,2006,16(11):1105-1111.
  • [1] 姚立新 , 付占昭 , 顾涛 , 郭雷鸣 , 华海侠 , 张庆怀 . 99Tcm-甲氧基异丁基异腈SPECT评价非小细胞肺癌化疗疗效. 国际放射医学核医学杂志, 2009, 33(5): 272-274. doi: 10.3760/cnla.j.issn.1673-4114.2009.05.005
    [2] 董峰 , 周荫保 . 分化型甲状腺癌术后131I清甲效果的影响因素. 国际放射医学核医学杂志, 2010, 34(1): 27-31. doi: 10.3760/cma.j.issn.1673-4114.2010.01.007
    [3] 杨爱民 , 彭志远 , 胡国瑛 , 孟宪文 . 99mTc-MIBI:用于肿瘤阳性显像. 国际放射医学核医学杂志, 1996, 20(6): 257-259.
    [4] 龙再颖 , 曲新艳 , 单英丽 . 99Tcm-MIBI显像对甲状腺结节良恶性鉴别诊断价值的研究. 国际放射医学核医学杂志, 2010, 34(2): 80-83. doi: 10.3760/cma.j.issn.1673-4114.2010.02.004
    [5] 胡旻 , 刘雅洁 , 许小飞 , 盛丹丹 , 王颖 . 99Tcm-MIBI动态血流灌注显像和双时相核素显像对甲状腺冷结节良恶性的诊断价值研究. 国际放射医学核医学杂志, 2010, 34(3): 174-176. doi: 10.3760/cma.j.issn.1673-4114.2010.03.013
    [6] 李宇轩 , 张禹 , 林志毅 , 苏耀东 , 石远颖 , 陈文新 . 99Tcm-3PRGD2 SPECT/CT显像在不摄碘进展性放射性碘难治性分化型甲状腺癌中的诊断价值. 国际放射医学核医学杂志, 2023, 47(5): 281-288. doi: 10.3760/cma.j.cn121381-202301001-00304
    [7] 李敬彦 , 蒋宁一 . 分化型甲状腺癌术后131I清甲治疗方法的相关问题. 国际放射医学核医学杂志, 2014, 38(1): 42-47. doi: 10.3760/cma.j.issn.1673-4114.2014.01.009
    [8] 咸雨蔚 , 左书耀 . 甲状腺肿瘤SPECT-CT融合显像的应用近况. 国际放射医学核医学杂志, 2006, 30(3): 157-160.
    [9] 易艳玲 , 卓维海 . 131I治疗甲状腺肿瘤患者出院剂量指导水平分析. 国际放射医学核医学杂志, 2008, 32(6): 372-375.
    [10] 侯仁花 , 吕中伟 . 生长抑素受体显像剂99mTc-depreotide的研究进展. 国际放射医学核医学杂志, 2008, 32(1): 15-18.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1719
  • HTML全文浏览量:  183
  • PDF下载量:  2
出版历程
  • 收稿日期:  2009-06-04

99Tcm-甲氧基异丁基异腈显像在分化型甲状腺癌随访中的应用

  • 中国医学科学院北京协和医院核医学科, 北京 100730
  • 收稿日期: 2009-06-04

摘要: 分化型甲状腺癌(DTC)在经过手术、放射性碘治疗、甲状腺激素抑制治疗后,仍需终身随诊。目前DTC的日常随诊方法如常规影像学方法、甲状腺球蛋白测定和131I全身显像仍有其不足之处,临床上常常发现一些患者存在不摄碘的失分化病灶,定位这些失分化的病灶,对确定患者的进一步治疗至关重要。肿瘤阳性显像剂99Tcm-甲氧基异丁基异腈(99Tcm-MIBI),由于其良好的物理和剂量测量方面的特性,价格便宜,国内外对其在DTC随访中的作用做了大量基础及临床研究。本综述主要从原理、显像方法、显像结果分析、优势介绍99Tcm-MIBI显像在DTC随访的应用。

English Abstract

    全文HTML

参考文献 (23)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net